CellPro, Corixa deal

CPRO will fund research at Corixa to identify and optimize methods and conditions to grow, activate or stimulate tumor antigen-specific lymphocytes and other antigen-presenting cells ex vivo for use in treating cancer. The agreement will use CPRO's ex vivo cell separation and cell culture technology with Corixa's knowledge and access to tumor antigens, antigen delivery systems and adjuvants. ...